Smart scans and DNA tests guide lymphoma therapy in new trial

NCT ID NCT06050694

Recruiting now Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Apr 24, 2026 · Last updated May 22, 2026 · Updated 6 times

Summary

This study tests a personalized approach for people with untreated diffuse large B-cell lymphoma (DLBCL). After initial chemotherapy, doctors use PET scans and blood DNA tests to decide if a patient can safely get less chemotherapy or needs a stronger drug called glofitamab. The goal is to improve outcomes while reducing side effects. About 40 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Jewish General Hospital
RECRUITING

Montreal, Quebec, H3T 1E2, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••
Princess Margaret Cancer Centre
NOT_YET_RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)